Vaxsyna's innovative vaccine platform for avian infectious bronchitis virus
VaxSyna's patented vaccine platform combines human antibodies with target antigens for a self-assembling, highly immunogenic complex. It aims to induce a robust immune response against avian IBV without adjuvants, enhancing efficacy and reducing doses.
Overview
VaxSyna presents a cutting-edge vaccine platform designed to combat avian infectious bronchitis virus (IBV) by targeting conserved proteins. This innovative solution leverages a unique self-assembly mechanism where human antibodies, vaccine antigens, and an epitope tag combine to form highly immunogenic complexes. These complexes effectively induce a strong immune response with just 1-2 doses, eliminating the need for adjuvants and offering a potentially extended duration of immunogenicity.
Technical specifications
- Vaccine Composition: The platform integrates a human antibody, target antigens (such as spike proteins S1 and S2), and an epitope tag.
- Mechanism of Action: These components self-assemble into complexes that directly target antigen-presenting cells (APCs), cross-link FcγR receptors, and facilitate antigen cross-presentation to T cells, enhancing immune response.
- Administration and Expression: The vaccine is expressed as recombinant and mRNA forms and can be administered via various routes to optimize efficacy.
- Production and Stability: Utilizes protein A/G affinity for improved solubility and stability.
Technology readiness level
The vaccine platform is at Technology Readiness Level 3, indicating that it is in the early stages of experimental proof of concept. Future efforts involve validation in collaboration with partners like Tri-Link and Celltheon, aiming for a 60% protective efficacy in chickens within one year.
About VaxSyna
VaxSyna is a biotechnology company that develops a modular, patented vaccine platform designed to address infectious diseases and other global health challenges. The company's technology utilizes self-assembling, higher-order antibody complexes that display multiple antigens on a human IgG backbone. This configuration triggers an immune response through Fc-receptor binding and crosslinking, enabling the development of highly immunogenic vaccines that can function without the need for chemical adjuvants. The platform is engineered to be easily modifiable for different target antigens and is manufactured using a transient, plant-based expression system in Nicotiana benthamiana, which allows for rapid, high-yield production of recombinant proteins.
The company focuses on creating vaccines that are thermally stable and cost-effective, with the goal of improving vaccine accessibility in low-to-middle-income countries. VaxSyna’s lead product candidates include prophylactic and therapeutic vaccines targeting HPV and herpes simplex virus. By utilizing optimized plant expression systems, the company aims to significantly lower manufacturing costs compared to current market standards. VaxSyna, which was founded in 2020 and is headquartered in the United States, has utilized federal grant funding to advance its research, including proof-of-concept studies to characterize its broad-spectrum HPV cancer vaccine candidate.
delivered to your inbox.